Johnson & Johnson’s (J&J) single-dose COVID-19 vaccine will be considered by the Food and Drug Administration on Friday, February 26, and if approved, the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) would meet shortly thereafter, and Johnson & Johnson’s COVID-19 vaccines could begin being used in the United States. The federal government has contracted with J&J to deliver 100 million doses of its vaccine by the end of June, if it is approved.
In This Issue
- Next Book Club Discussion March 2; Read the Book and Register Today
- Black Representation in Medicine: A Roundtable Discussion
- Dr. Bachelder Contributes to Voices in Humanism Collection
- OAFP Mourns the Passing of Dr. Dinah Fedyna
- COVID-19 Vaccine Town Halls for At-Risk Populations to Address Vaccine Hesitancy
- Now Accepting 2021 Award Nominations
- Sandra. L. Panther Fellowship Application Now Open
- Biden Administration Expected to Rescind Medicaid Work Requirements
- COVID Vaccine Distribution Update
- Got Your Vaccine? Get a Shirt & Mask to Match
- COVID-19 Vaccine Maintenance Program for Nursing Home Residents and Staff
- It’s Official: AAFP TIPS™ Is Now Free to Members
- Nursing Home Cases Drop Drastically
- Getting K-12 Students Back in the Classroom
- Johnson & Johnson Submits EUA Application
- Daily Vaccination Rates in Ohio Increasing
- Rent Assistance for Those Suffering Due to Pandemic
- Ohio Corrects COVID Death Data Collection Error
- Stay Connected to the OAFP and OAFP Foundation on Social Media
- Free CME Practice Management Webinar Series – On Demand
Comments
Leave a Comment
Your email address will not be published. Required fields are marked *